- Home
- SATL vs LXRX Comparison
SATL vs LXRX Comparison
Compare SATL & LXRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SATL | LXRX |
|---|---|---|
| Founded | 2010 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 482.3M | 547.4M |
| IPO Year | N/A | 2000 |
Fundamental Metrics
Financial Performance| Metric | SATL | LXRX |
|---|---|---|
| Price | $3.38 | $1.64 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $6.00 | $3.23 |
| AVG Volume (30 Days) | ★ 4.9M | 2.3M |
| Earning Date | 01-01-0001 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 21.25 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $31,081,000.00 |
| Revenue This Year | $16.18 | $56.61 |
| Revenue Next Year | $92.36 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 2481.48 |
| 52 Week Low | $1.26 | $0.32 |
| 52 Week High | $5.93 | $1.83 |
Technical Indicators
Market Signals| Indicator | SATL | LXRX |
|---|---|---|
| Relative Strength Index (RSI) | 50.75 | 64.63 |
| Support Level | $3.23 | $1.07 |
| Resistance Level | $3.94 | $1.65 |
| Average True Range (ATR) | 0.31 | 0.10 |
| MACD | -0.02 | 0.02 |
| Stochastic Oscillator | 57.08 | 93.42 |
Price Performance
Historical ComparisonAbout SATL Satellogic Inc.
Satellogic Inc is a provider of satellite imagery to governments and commercial customers globally. It geographically operates in North America, Europe, Asia and South America. It derives maximum revenue from Asia Pacific.
About LXRX Lexicon Pharmaceuticals Inc.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, also developing LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.